KARLSKOGA, Sweden, Nov. 11, 2025 /PRNewswire/ — Last year, Cell Impact was awarded silver by EcoVadis. This year, the company has received a gold medal.
EcoVadis, the world’s most trusted provider of sustainability ratings, has evaluated Cell Impact’s operational sustainability practices. The overall score has improved from 72 to 79 of 100, which places the company among the top 5 percent of all rated companies.
“The increase is primarily due to improvements in reporting, but also in routines and follow-up across several areas. This isn’t rocket science—we set goals, follow up, and continuously improve,” says Daniel Vallin, CEO of Cell Impact.
“Since our flow plates are essential for the global energy transition, it feels great to have been awarded a gold rating by EcoVadis as well.” Daniel Vallin concludes.
For more information, please contact:
Daniel Vallin
CEO and IR contact, Cell Impact AB (publ)
+46730686620 or daniel.vallin@cellimpact.com
About Cell Impact
Cell Impact AB (publ) is a global supplier of advanced flow plates to fuel cell and electrolyzer manufacturers. The company has developed and patented a unique method for high velocity forming, Cell Impact Forming™ which is significantly more scalable and cost-efficient compared to conventional forming methods. Cell Impact Forming is an environmentally friendly forming technology that consumes no water and very little electrical power.
The Cell Impact share is listed on Nasdaq First North Growth Market and FNCA Sweden AB is the company’s Certified Advisor (CA).
Photo: https://mma.prnewswire.com/media/2819968/EcoVadis_Rating.jpg
PDF: https://mma.prnewswire.com/media/2819969/Cell_Impact_Pressrelease.pdf
Logo: https://mma.prnewswire.com/media/2816030/5615566/Cell_Impact_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/cell-impact-has-been-awarded-gold-medal-by-ecovadis-302611812.html
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…
MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…
SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…
Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…
– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…
- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…